Amplia Therapeutics Ltd
ASX:ATX

Watchlist Manager
Amplia Therapeutics Ltd Logo
Amplia Therapeutics Ltd
ASX:ATX
Watchlist
Price: 0.125 AUD 4.17% Market Closed
Market Cap: 64.1m AUD

Operating Margin
Amplia Therapeutics Ltd

-166.3%
Current
-230%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-166.3%
=
Operating Profit
-8.3m
/
Revenue
5m

Operating Margin Across Competitors

No Stocks Found

Amplia Therapeutics Ltd
Glance View

Market Cap
64.1m AUD
Industry
Biotechnology

Amplia Therapeutics Ltd. is a medical biotechnology company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2013-12-23. The Company’s pipeline is developing two orally available small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its initial clinical development pipeline consists of AMP945 and AMP886 (FLT3/VEGFR3). The Company’s cancer program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its Fibrosis Program is the formation of excessive fibrous connective tissues that can result from chronic inflammation, chronic injury or disease. Its FAK inhibitors have been shown to block fibrosis in established animal models of both lung fibrosis and liver fibrosis (NASH).

ATX Intrinsic Value
0.14 AUD
Undervaluation 10%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-166.3%
=
Operating Profit
-8.3m
/
Revenue
5m
What is the Operating Margin of Amplia Therapeutics Ltd?

Based on Amplia Therapeutics Ltd's most recent financial statements, the company has Operating Margin of -166.3%.

Back to Top